EUCTR2008-000905-12-IT进行中（未招募）不适用
A single dose, randomized, double blind, double dummy, placebo controlled, three-period crossover clinical study, comparing the onset of relief from methacholine induced bronchoconstriction with fixed combination beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/actuation pMDI with HFA-134a propellant (Foster) versus standard salbutamol pMDI 100 µg/actuation (Ventolin Evohaler) therapy in asthmatic patients. - MART 1 Maintenance And Reliever Therapy
CHIESI0 个研究点开始时间: 2008年10月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject?s written informed consent. 2. Outpatients of both sexes aged 18 years. 3. Diagnosis of asthma for a minimum of 6 months prior to Visit 1. The evidence of asthma must be confirmed through a documented positive response to the reversibility test, defined as ΔFEV1 ≥ 12% and ≥ 200 mL over baseline, within 30 minutes after administration of 400 μg of salbutamol pMDI or through a positive response to methacholine challenge test (PC20 < 8 mg/mL or PD20 < 1 mg). In case this is not achieved, a positive historically documented FEV1 reversibility or response to methacholine challenge test within the previous 6 months is acceptable for the diagnosis of asthma. The investigator, according to his/her clinical judgment, will decide about performing the reversibility test or the methacholine challenge test. 4. Baseline FEV1 > 70% of the predicted normal value and at least 1.5 L, after appropriate washout from bronchodilators. 5. Patients on previous treatment with low-medium doses of ICS (200 - 1000 μg BDP CFC daily or equivalent) or ICS + LABA fixed or free combinations (daily dose of budesonide 200 - 800 µg/fluticasone 100 - 500 µg or equivalent ICS doses plus formoterol 12 - 24 µg or salmeterol 50 - 100 μg) at a stable dose for at least 2 months prior to inclusion. The fixed combination therapies must be switched to the free components ICS alone at the same dose + LABA alone at the same dose in order to stop LABA only 48 hours before each clinic visit. 6. A cooperative attitude and ability to be trained about the proper use of a pMDI.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients with other lung diseases such as (but not limited to) COPD (Chronic Obstructive Pulmonary Disease), cystic fibrosis, interstitial lung diseases or any other clinically or functionally significant lung disorder. 2. Patients who experienced an acute bronchoconstriction induced by methacholine that, according to the investigator?s opinion, could not be easily managed through SABAs. 3. Patients having received an investigational drug within 2 months. 4. Patients having suffered from a heart attack or stroke within the previous 3 months. 5. Patients with a known aortic or cerebral aneurysm. 6. Patients suffering from uncontrolled hypertension (systolic pressure > 200 and/or diastolic pressure > 110 mmHg). 7. Patients who suffer from uncontrolled cardiovascular, respiratory, haematological, immunologic, renal, neurologic, hepatic, endocrinal or other diseases, as well as any condition that might, in the judgement of the investigator, represent for the patients an undue risk or that could compromise the results or the interpretation of the study. 8. Clinically relevant laboratory abnormalities such as (but not limited to) hypokaliemia, that might compromise patient?s safety or compliance, interfere with evaluation, or preclude completion of the study, in the judgment of the investigator. 9. Patients with uncontrolled diabetes including patients with a history of blood glucose levels consistently out of the normal range or HbA1C > 8.0% measured at V1. 10. Patients who have an abnormal QTC interval value in the screening visit ECG test (i.e., > 450 msec in males or > 470 msec in females). 11. Use of systemic steroids within 6 weeks prior to Visit 1. 12. Intolerance/hypersensitivity or contra-indication to treatment with β2-agonists and/or inhaled steroids. 13. Any change in dose, schedule, formulation or product of previous ICS or fixed/free combination ICS + LABA in the 2 months prior to screening visit. 14. Moderate/severe exacerbation and/or intake of oral corticosteroids during the run-in period. 15. Patients treated with slow-release corticosteroids in the 3 months prior to screening visit. 16. Patients being treated with anti-IgE antibodies. 17. Latest moderate/severe asthma exacerbation within 6 weeks. 18. Inability to comply with study procedures or with study treatment intake. 19. Significant response to the diluents, (i.e., > 15% fall in FEV1 from the patient?s FEV1 at baseline, prior to commencing the methacholine challenge test). 20. Upper or lower respiratory tract infection within the previous 6 weeks. 21. History of near fatal asthma. 22. Any acute or clinical condition that put the patient at risk or may alter the interpretation of the test. 23. Pregnant or lactating women. Females of childbearing potential without an efficient contraception. 24. Use of coffee, tea, cola drinks, chocolate, or other foods containing caffeine 8 hours before the challenge test. 25. Strenuous exercise in the last 2 hours before the challenge. 26. Previous or current smokers who have a smoking history greater that 5 pack years. Current smoking for 1 hour before the challenge test. 27. Patients having received a live-attenuated virus vaccination within 2 weeks prior to screening or during the run-in period. 28. Major surgery in the previous 3 months.
研究者
相似试验
进行中（未招募）
不适用
A single dose, randomized, double blind, double dummy, placebo controlled, three-period crossover clinical study, comparing the onset of relief from methacholine induced bronchoconstriction with fixed combination beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/actuation pMDI with HFA-134a propellant (Foster®) versus standard salbutamol pMDI 100 µg/actuation (Ventolin® 100 µg) therapy in asthmatic patients - MART1AsthmaEUCTR2008-000905-12-GBCHIESI FARMACEUTICI S.p.A.54
进行中（未招募）
不适用
A single dose, randomised, double blind, double dummy, placebo-controlled, three-period crossover clinical study, comparing the efficacy, safety and tolerability of Formoterol-HFA pMDI 12 microgram per actuation administered by means of a spacer device (AeroChamber Plus) with that of Formoterol-HFA pMDI 12 microgram per actuation in 5- to 12-year-old children with persistent moderate to severe asthmaPersistent moderate to severe childhood asthma (5 to 12 years of age, inclusive)MedDRA version: 8.1Level: PTClassification code 10049585EUCTR2006-000907-41-HUChiesi Farmaceutici S.p.A.42
进行中（未招募）
1 期
A clinical trial to investigate the comparability of relief from methacholine-induced bronchoconstriction with CHF1535 100/6 µg NEXThaler® versus CHF1535 100/6 µg pMDI in asthmatic patients.MedDRA version: 19.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2016-003672-47-GBChiesi Farmaceutici S.p.A.60
招募中
Unknown
To evaluate the Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers Containing Albuterol Sulfate in Adult Patients with Stable Mild AsthmaCTRI/2024/03/064870Intech Biopharm Limited
已完成
不适用
To check the difference of two products that is product A (Xtenergy caffeine 60%, 200 mg caffeine/ Capsule) and product B (Natural caffeine extract 99%,200 mg caffeine/Capsule) in the healthy adult human beings.CTRI/2019/11/022135OmniActive Health Technologies Ltd26